基于形态特征提取的急性下壁心肌梗死BiLSTM网络辅助诊断算法

急性下壁心肌梗死是一种病发急、进展快、致死率高的心脏疾病,该文提出一种新颖的基于形态特征提取的BiLSTM神经网络分类的急性下壁心肌梗死辅助诊断算法,可大幅度提高医生对急性下壁心肌梗死疾病的诊断效率并有助于及时确诊.算法包括:对胸痛中心数据库心拍信号进行降噪及心拍分割;根据临床心内科医学诊断指南提取了12导联波形距离特征和分导联波形幅值特征;依据提取的特征搭建LSTM与BiLSTM神经网络进行心拍的分类识别;使用PTB公开数据库和胸痛中心数据库多临床中心进行交叉验证.实验结果表明,加入胸痛中心真实临床数据后,基于形态特征提取BiLSTM神经网络的急性下壁心肌梗死辅助诊断算法准确率达到99.72％,精度达到99.53％,灵敏度达到100.00％,同时F1-Score达到99.76.该算法比其他现有算法准确率提高至少1％,该项研究具有非常重要的临床应用价值.     

北斗星历解析及实时卫星位置解算实现

利用 C 语言编程进行北斗卫星星历数据的实时读取，更新结构体的卫星轨道参数， 从而实现北斗卫星位置的解算，并与武汉大学数据中心提供的北斗精密星历作比较，对解算的卫星位置结果进行评估，最大误差不超过 3.5 米，满足实际应用需要。     

Nickel/Photoredox-Catalyzed Asymmetric Reductive Cross-Coupling of Racemic α-Chloro Esters with Aryl Iodides

A unique nickel/organic photoredox co-catalyzed asymmetric reductive cross-coupling between α-chloro esters and aryl iodides is developed. This cross-electrophile coupling reaction employs an organic reductant (Hantzsch ester), whereas most reductive cross-coupling reactions use stoichiometric metals. A diverse array of valuable α-aryl esters is formed under these conditions with high enantioselectivities (up to 94 %) and good yields (up to 88 %). α-Aryl esters represent an important family of nonsteroidal anti-inflammatory drugs. This novel synergistic strategy expands the scope of Ni-catalyzed reductive asymmetric cross-coupling reactions.     

Direct Transformation of Arenols Based on C—O Activation

In the view of substrate availability, atomic efficiency and cost, directly using arenols as coupling partners in cross‐coupling, would be one of the most attractive goals. Up to date, many efforts have been made to activate the C—O bond of phenols with different strategies, for example, through in‐situ formed intermediates, through a catalytic reductive dearomatization‐condensation‐rearomatization sequence or catalytic deoxygenation. In this review, we summarized recent advances in cross‐couplings of arenols as the electrophiles via C—O activation.     

Syntheses,Characterization, and Luminescence Properties of Three Coordination Complexes with Sulfonate-Phenol Anions and Trivalent Metal Ions

Russian Journal of General Chemistry - A dinuclear Tb complex, Tb2(H2L)3(phen)2 (1), and two similar N-donor coordination complexes, Fe(phen)3·HL (2), Fe(bipy)3·HL·5H2O (3) (Na2H2L =...     

蛋白质-多糖复合体系在活性物质传递中的应用

蛋白质-多糖复合体系作为生物活性物质传递系统的壁材,有着人工合成聚合物或无机物等其他材料不可比拟的多重优势。本文就蛋白质和多糖之间的连接方式及蛋白质-多糖复合体系形成传递系统的多种形式进行了综述,以及对此领域的发展趋势进行了展望。结合蛋白质和多糖的结构特点,二者之间的链接方式分为非共价结合的物理共聚,和共价结合的美拉德偶联、化学交联、酶催化交联等方式,文中分别对各种连接方式的原理和机理,以及其影响因素做了深入阐述。以蛋白质-多糖复合体系为壁材对活性物质的传递形式大体上分成乳化系统、胶束、纳米凝胶、分子复合物以及壳核结构等系统。不同的活性物质的特征和传递需求,可针对性地选择合适结构的蛋白质和多糖种类以及二者的连接方式和传递系统的形式。并且,随着研究的逐步发展和推进,此领域的发展趋势朝着智能化和靶向性的方向进行。目前活性物质的蛋白质-多糖复合体系的传递系统,还依然面临着系统设计、评价和应用等多方面的挑战,这就要求我们在更全面更深入了解认识其对活性物质影响和功效的基础上,安全合理地设计和深入细致地评价活性成分的传递系统。     

A novel LC–MS/MS method for the determination of ziritaxestat in rat plasma and its pharmacokinetic study

Ziritaxestat is a first-in-class autotoxin inhibitor. The purpose of this study was to develop a liquid chromatography/electrospray ionization tandem mass spectrometric (LC–MS/MS) method for the determination of ziritaxestat in rat plasma. The plasma sample was deproteinated using acetonitrile and then separated on an Acquity BEH C₁₈ column with water containing 0.1% formic acid and acetonitrile as mobile phase, which was delivered at 0.4 ml/min. Ziritaxestat and the internal standard (crizotinib) were quantitatively monitored with precursor-to-product transitions of m/z 589.3 > 262.2 and m/z 450.1 > 260.2, respectively. The total running time was 2.5 min. The method showed excellent linearity over the concentration range 0.5–2000 ng/ml, with correlation coefficient >0.9987. The extraction recovery was >82.09% and the matrix effect was not significant. Inter- and intra-day precisions (RSD) were <11.20% and accuracies were in the range of −8.50–7.45%. Ziritaxestat was demonstrated to be stable in rat plasma under the tested conditions. The validated LC–MS/MS method was successfully applied to study the pharmacokinetic profiles of ziritaxestat in rat plasma after intravenous and oral administration. Pharmacokinetic results demonstrated that ziritaxestat displayed a short half-life (~3 h) and low bioavailability (20.52%).